Investigation of the effect of silymarin on the liver in experimental sepsis

Year 2015, Volume: 19 Issue: 1, 52 - 59, 06.01.2015

Burcu Cihan Ayşen Yarat , Tuba Tunalı Akbay Göksel Şener

Abstract

ABSTRACT
The aim of the study is to investigate the possible protective
effect of silymarin (extract of Silybum marianum) on the
liver of septic rats was at early stage of sepsis. Polymicrobial
sepsis was induced by the cecal ligation and perforation
(CLP) technique. Sepsis and sepsis + silymarin treated
groups received vehicle or silymarin (50 mg/kg, orally). The
rats were decapitated 6 h after the CLP procedure. Protein,
glutathione, lipid peroxidation levels, tissue factor activity
and some enzyme activities were determined and
polyacrylamid gel electrophoresis was carried on liver
samples. TNF-a, IL-1b and IL-6 were determined in blood
samples. Glutathione levels significantly increased and
tissue factor activity significantly decreased in both sepsis
and sepsis+silymarin treated groups when compared with
control. Superoxide dismutase activity significantly
decreased in sepsis+silymarin treated group when compared
control and sepsis groups. No significant difference was
found in electrophoresis protein bands. Blood
proinflammatory cytokine levels were significantly
decreased in silymarin treated sepsis group when compared
with sepsis group. The effect of silymarin was not apparent
since oxidative damage was not obvious in liver
consequently it can be suggested that some protective
mechanisms related with glutathione in liver may be
involved in early stage sepsis.
Key Words: Sepsis, Silymarin, Liver, Tissue factor, Oxidative stress

Keywords

-

ORIGINAL RESEARCH

Abstract

References

• Bannister, BA, Begg, NT, Gillespie, SH. Infectious Disease. Oxford: Blackwell Science Ltd, 2000; 361-78.
• Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29: 1303-10.
• Vincent JL, Abraham E. The last 100 years of sepsis. Am J Res Crit Care Med 2006; 173: 256-63.
• Angus DC, Crowther MA. Unraveling Severe Sepsis: Why Did OPTIMIST Fail and What’s Next? J Am Med Assoc 2003; 290: 256-8.
• Lopes-Bezerra LM, Filler SG. Endothelial cells, tissue factor and infectious diseases. Brazilian J Med Biol Res 2003; 36: 987-91.
• Prucha M, Bellingan G, Zazula R. Sepsis biomarkers. Clin Chim Acta 2014; 18;440C:97-103
• Cawcutt KA, Peters SG. Severe Sepsis and Septic Shock: Clinical Overview and Update on Management. Mayo Clin Proc. 2014;89:1572-8.
• Rainone F. Milk thistle. Am Fam Physician 2005;72: 1285-8.
• Sonnenbichler, J., Scalera, F., Sonnenbichler, I., Weyhenmeyer, R. Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther 1999; 290: 1375- 83.
• Kren V, Walterova D. Silybin and silymarin-new effects and applications. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 2005; 149: 29-41.